Mara Goldstein
Stock Analyst at Mizuho
(2.82)
# 1,888
Out of 4,996 analysts
77
Total ratings
44.83%
Success rate
8.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $9.05 | +231.49% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.11 | +373.93% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $8.89 | -10.01% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $12.84 | +227.10% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $11.57 | +332.15% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $15.68 | +186.99% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $82.70 | -6.89% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.08 | +236.54% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.00 | +700.00% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.35 | +3,328.57% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $58.50 | +53.85% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $7.39 | -52.64% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.29 | +15,620.52% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $8.08 | +147.52% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $78.56 | +65.48% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $2.90 | -31.03% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.56 | +669.23% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.15 | +6,022.45% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $50.40 | -60.32% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $8.26 | +481.11% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.14 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.54 | +152.71% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $9.05
Upside: +231.49%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.11
Upside: +373.93%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $8.89
Upside: -10.01%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $12.84
Upside: +227.10%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $11.57
Upside: +332.15%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $15.68
Upside: +186.99%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $82.70
Upside: -6.89%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.08
Upside: +236.54%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.00
Upside: +700.00%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.35
Upside: +3,328.57%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $58.50
Upside: +53.85%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $7.39
Upside: -52.64%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.29
Upside: +15,620.52%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $8.08
Upside: +147.52%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $78.56
Upside: +65.48%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $2.90
Upside: -31.03%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.56
Upside: +669.23%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.15
Upside: +6,022.45%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $50.40
Upside: -60.32%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $8.26
Upside: +481.11%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $26.14
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.54
Upside: +152.71%